134,138 Medtronic PLC $MDT Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 7.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,885,095 shares of the medical technology company’s stock after buying an additional 134,138 shares during the period. Russell Investments Group Ltd.’s holdings in Medtronic were worth $162,705,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Activest Wealth Management boosted its position in shares of Medtronic by 470.9% in the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 259 shares during the period. IAG Wealth Partners LLC acquired a new stake in shares of Medtronic in the second quarter worth $30,000. Team Financial Group LLC acquired a new stake in shares of Medtronic in the third quarter worth $31,000. Avion Wealth increased its position in Medtronic by 97.8% during the third quarter. Avion Wealth now owns 362 shares of the medical technology company’s stock worth $31,000 after acquiring an additional 179 shares during the period. Finally, Pin Oak Investment Advisors Inc. bought a new position in Medtronic during the second quarter worth $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Barclays upgraded shares of Medtronic to a “hold” rating in a research note on Wednesday, October 7th. Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Wednesday, October 14th. BTIG Research cut their price objective on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Weiss Ratings raised shares of Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 19th. Finally, Stifel Nicolaus increased their target price on shares of Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research note on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Get Our Latest Analysis on MDT

Medtronic Stock Performance

Shares of NYSE MDT opened at $102.84 on Monday. The business has a fifty day simple moving average of $93.72 and a 200 day simple moving average of $88.47. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $131.54 billion, a price-to-earnings ratio of 25.33, a PEG ratio of 2.41 and a beta of 0.56. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same period last year, the business earned $1.26 earnings per share. Medtronic’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Sell-side analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were paid a $0.72 dividend. The ex-dividend date was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s dividend payout ratio is currently 70.94%.

Insider Activity

In other news, CEO Geoffrey Martha sold 50,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer directly owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This trade represents a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares of the company’s stock, valued at $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by corporate insiders.

About Medtronic

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Further Reading

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.